High risk BCG-unresponsive non-muscle invasive bladder cancer
| Drug | Drug Name | Drug Description |
|---|---|---|
| DB17381 | Nadofaragene firadenovec | A non-replicating adenoviral vector-based gene therapy used to treat high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS). |
| Drug | Drug Name | Target | Type |
|---|
| Drug | Drug Name | Phase | Status | Count |
|---|